The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of ...
Sep 13, 2022
0
20
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type, according to results from the international ...
Aug 12, 2022
0
36
Scientists have identified a new treatment combination that is highly effective at suppressing the growth of head and neck tumors.
Jun 16, 2022
0
5
New research led by Dr. John Maher, from the School of Cancer & Pharmaceutical Sciences, working for Leucid Bio and with biotech company LUMICKS, has been published in the February 2022 issue of Frontiers in Immunology.
Mar 8, 2022
0
7
Over the past two decades, targeted cancer therapies have changed the prognosis for thousands of patients. By targeting the specific genetic mutation behind a patient's cancer, these therapies have enabled increasing numbers ...
Jun 21, 2021
0
2
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and 12.5 months median overall survival in previously treated ...
Jun 4, 2021
0
1
Human T-cell lymphotropic virus type-1 (HTLV-1) is a retrovirus similar to human immunodeficiency virus (HIV) and has mostly been thought to be transmitted vertically (mother-to-child), or horizontally (sexually or parenterally ...
Apr 27, 2021
0
4
A technique that delivers high-intensity focused ultrasound to targeted tissue under MRI guidance effectively treats intermediate-risk prostate cancer with minimal side effects, according to a study published in Radiology.
Feb 2, 2021
0
1
Researchers from Queen Mary University of London, have identified a protein that may represent a novel therapeutic target for the treatment of pancreatic cancer. Using this protein as a target, the team successfully created ...
Jan 22, 2021
0
36
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) have identified a potential drug combination to treat uveal melanoma, a type of eye cancer. Lead author Amanda Truong, trainee in the McMahon ...
Dec 3, 2020
0
5
